CXBS (Corix Bioscience) EBIT: $-4.94 Mil (TTM As of Sep. 2017)


What is Corix Bioscience EBIT?

Corix Bioscience CXBS -99.00% EBIT is $-4.94 Mil as of Sep. 2017.

Corix Bioscience's earnings before interest and taxes (EBIT) for the three months ended in Sep. 2017 was $-0.28 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Sep. 2017 was $-4.94 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Corix Bioscience's annualized ROC % for the quarter that ended in Sep. 2017 was -16.81%. Corix Bioscience's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2017 was -75.03%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield.

Corix Bioscience  (OTCPK:CXBS) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Corix Bioscience's annualized ROC % for the quarter that ended in Sep. 2017 is calculated as:

ROC % (Q: Sep. 2017 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2017 ) + Invested Capital (Q: Sep. 2017 ))/ count )
=-1.2 * ( 1 - 0% )/( (10.333 + 3.947)/ 2 )
=-1.2/7.14
=-16.81 %

where

Invested Capital(Q: Jun. 2017 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=10.457 - 0.827 - ( 0.144 - max(0, 1.205 - 0.502+0.144))
=10.333

Invested Capital(Q: Sep. 2017 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=4.344 - 0.036 - ( 0.361 - max(0, 0.786 - 4.011+0.361))
=3.947

Note: The Operating Income data used here is four times the quarterly (Sep. 2017) data.

2. Joel Greenblatt's definition of Return on Capital:

Corix Bioscience's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2017 is calculated as:

ROC (Joel Greenblatt) %(Q: Sep. 2017 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2017  Q: Sep. 2017
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-1.124/( ( (0 + max(-0.906, 0)) + (0.082 + max(2.914, 0)) )/ 2 )
=-1.124/( ( 0 + 2.996 )/ 2 )
=-1.124/1.498
=-75.03 %

where Working Capital is:

Working Capital(Q: Jun. 2017 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0.28) - (0.827 + 0 + 0.359)
=-0.906

Working Capital(Q: Sep. 2017 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0.045 + 3.605) - (0.036 + 0 + 0.7)
=2.914

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Sep. 2017) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Corix Bioscience's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Sep. 2017 )
=-4.941/0.000
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Corix Bioscience EBIT Related Terms

Corix Bioscience EBIT Historical Data

* Premium members only.

The historical data trend for Corix Bioscience's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Corix Bioscience EBIT Chart

Corix Bioscience Annual Data
Trend Jan09 Jan10 Jan11 Jan12 Jan13 Jan14 Jan15 Dec16
EBIT
Get a 7-Day Free Trial -0.08 -1.70 -1.72 -0.05 -4.05

Corix Bioscience Quarterly Data
Oct12 Jan13 Apr13 Jul13 Oct13 Jan14 Apr14 Jul14 Oct14 Jan15 Apr15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.33 -3.14 -0.07 -1.46 -0.28

CXBS vs BKIT, YBAO, HSTI: EBIT Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Corix Bioscience's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Corix Bioscience EV-to-EBIT vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Corix Bioscience's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Corix Bioscience's EV-to-EBIT falls into.


Corix Bioscience EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Sep. 2017 adds up the quarterly data reported by the company within the most recent 12 months, which was $-4.94 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of $-4.94 Mil mean?
Corix Bioscience (CXBS) has a EBIT of $-4.94 Mil as of Sep. 2017. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Corix Bioscience.
Is Corix Bioscience's EBIT too high?
Corix Bioscience's current EBIT is $-4.94 Mil.
How does Corix Bioscience's EBIT compare to BKIT and YBAO?
Corix Bioscience's EBIT of $-4.94 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Drug Manufacturers company?
A good EBIT depends on the Drug Manufacturers industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Corix Bioscience. Corix Bioscience's current EBIT is $-4.94 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Corix Bioscience stock overvalued right now?
Corix Bioscience (CXBS) has a current EBIT of $-4.94 Mil. The current EBIT is $-4.94 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Corix Bioscience (CXBS), the current EBIT is $-4.94 Mil as of Sep. 2017. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Corix Bioscience Business Description

Address 18662 MaCaurther Boulevard, Suite 200, Irvine, CA, USA, 85085
Corix Bioscience Inc is a United States-based research and development firm of cannabidiol (CBD) products and treatments. It is engaged in the business of producing organic CBD oil used for medical applications and treatments. In addition, the group is also focused on the production of tetrahydrocannabivarin oil. The company is focused on operations in Oregon, California, and Nevada, United States.